Dr. Christophe Arbet-Engels serves as Chief Medical Officer of the Company. Dr. Arbet-Engels was appointed as our Chief Medical Officer in February 2020, bringing to us more than 25 years of experience in life sciences, academia and industry. From January 2017 to November 2019, Dr. Arbet-Engels served as Chief Medical Officer, Executive Vice President, Late Development and Medical Affairs at Poxel Pharmaceuticals, with responsibility for all medical activities for its portfolio, including driving portfolio strategy and executing registration programs. From August 2015 to October 2016, he served as Vice President, Worldwide Medical, Collaborative Medical Sciences at Biogen, where he built, developed and led global medical research, clinical operations, biostatistics/analytics, communication and expanded access program teams to advance the medical sciences in multiple therapeutic areas. From 2012 to 2015, he served as Vice President, Clinical Development and Medical Affairs at Boehringer Ingelheim, where he was the medical leader of the metabolism therapeutic area in the United States for portfolio and product development, registration, launch, and life-cycle strategy. From 2005 to 2012, he served as Clinical Science Leader, Metabolism-Cardiovascular Diseases at Hoffmann-La Roche, where he was the global medical lead for clinical development and registration of metabolism and cardiovascular products. From 2004 to 2005, he served as Director of Clinical Research at Merck Research Laboratories, where he was medical lead for early programs and for registration. From 2001 to 2004, he served as Medical Director, Metabolism, Global Medical Affairs and Marketing at Aventis Pharmaceuticals (now Sanofi), where he was responsible for the development of worldwide strategy and execution of clinical programs.
Christophe Engels is 58, he's been the Chief Medical Officer of Millendo Therapeutics since 2020. There are 6 older and 7 younger executives at Millendo Therapeutics. The oldest executive at Millendo Therapeutics, Inc. is John Howe, 77, who is the Independent Director.
Christophe's mailing address filed with the SEC is C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON, MA, 02134.
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
Millendo Therapeutics executives and other stock owners filed with the SEC include: